BLACK DIAMOND THERAPEUTICS, INC. Operating Income
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Operating Income of -$12.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$12.06M.
- BLACK DIAMOND THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$11.26M, a 120.65% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$17.61M.
- BLACK DIAMOND THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$10.98M.
- BLACK DIAMOND THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was $12.52M.
- BLACK DIAMOND THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$78.78M.
- BLACK DIAMOND THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$86.46M.
- BLACK DIAMOND THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$92.83M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.06M 10-Q · filed 2026-08-05 | -$23.32M 10-Q · filed 2026-08-05 | -$40.93M derived: sum of 3 quarters · filed 2026-08-05 | -$51.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$11.26M 10-Q · filed 2026-05-07 | -$28.87M derived: sum of 2 quarters · filed 2026-05-07 | -$39.85M derived: sum of 3 quarters · filed 2026-05-07 | -$53.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$17.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$28.59M derived: sum of 2 quarters · filed 2026-03-16 | -$42.01M derived: sum of 3 quarters · filed 2026-08-05 | $12.52M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$10.98M 10-Q · filed 2025-11-06 | -$24.40M derived: sum of 2 quarters · filed 2026-08-05 | $30.13M 10-Q · filed 2025-11-06 | $11.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$13.42M 10-Q · filed 2026-08-05 | $41.11M 10-Q · filed 2026-08-05 | $22.84M derived: sum of 3 quarters · filed 2026-08-05 | $4.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $54.53M 10-Q · filed 2026-05-07 | $36.26M derived: sum of 2 quarters · filed 2026-05-07 | $18.13M derived: sum of 3 quarters · filed 2026-05-07 | -$4.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$36.41M derived: sum of 2 quarters · filed 2026-03-16 | -$58.53M derived: sum of 3 quarters · filed 2026-03-16 | -$78.78M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$18.13M 10-Q · filed 2025-11-06 | -$40.26M derived: sum of 2 quarters · filed 2025-11-06 | -$60.51M 10-Q · filed 2025-11-06 | -$81.36M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$22.13M 10-Q · filed 2025-08-07 | -$42.38M 10-Q · filed 2025-08-07 | -$63.23M derived: sum of 3 quarters · filed 2025-08-07 | -$87.24M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$20.25M 10-Q · filed 2025-05-12 | -$41.10M derived: sum of 2 quarters · filed 2025-05-12 | -$65.11M derived: sum of 3 quarters · filed 2025-05-12 | -$85.14M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$20.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$44.87M derived: sum of 2 quarters · filed 2025-03-06 | -$64.90M derived: sum of 3 quarters · filed 2025-03-06 | -$86.46M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$24.01M 10-Q · filed 2024-11-05 | -$44.04M derived: sum of 2 quarters · filed 2024-11-05 | -$65.61M 10-Q · filed 2024-11-05 | -$87.46M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$20.03M 10-Q · filed 2024-08-06 | -$41.59M 10-Q · filed 2024-08-06 | -$63.45M derived: sum of 3 quarters · filed 2024-08-06 | -$85.57M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$21.56M 10-Q · filed 2024-05-09 | -$43.41M derived: sum of 2 quarters · filed 2024-05-09 | -$65.54M derived: sum of 3 quarters · filed 2024-05-09 | -$88.71M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$21.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$43.98M derived: sum of 2 quarters · filed 2024-03-12 | -$67.15M derived: sum of 3 quarters · filed 2024-03-12 | -$92.83M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$22.12M 10-Q · filed 2023-11-06 | -$45.30M derived: sum of 2 quarters · filed 2023-11-06 | -$70.98M 10-Q · filed 2023-11-06 | -$97.06M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$23.17M 10-Q · filed 2023-08-11 | -$48.85M 10-Q · filed 2023-08-11 | -$74.93M derived: sum of 3 quarters · filed 2023-08-11 | -$110.30M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$25.68M 10-Q · filed 2023-05-09 | -$51.76M derived: sum of 2 quarters · filed 2023-05-09 | -$87.12M derived: sum of 3 quarters · filed 2023-05-09 | -$121.84M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$26.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$61.44M derived: sum of 2 quarters · filed 2023-03-09 | -$96.16M derived: sum of 3 quarters · filed 2023-03-09 | -$126.87M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$35.36M 10-Q · filed 2022-11-08 | -$70.08M derived: sum of 2 quarters · filed 2022-11-08 | -$100.79M 10-Q · filed 2022-11-08 | -$123.97M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$34.72M 10-Q · filed 2022-08-09 | -$65.43M 10-Q · filed 2022-08-09 | -$88.61M derived: sum of 3 quarters · filed 2022-08-09 | -$107.09M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$30.71M 10-Q · filed 2022-05-11 | -$53.90M derived: sum of 2 quarters · filed 2022-05-11 | -$72.38M derived: sum of 3 quarters · filed 2022-05-11 | -$87.40M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$23.18M 10-K · filed 2021-03-25 | -$41.66M derived: sum of 2 quarters · filed 2021-11-08 | -$56.69M derived: sum of 3 quarters · filed 2021-11-08 | -$69.57M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$18.48M 10-Q · filed 2021-11-08 | -$33.51M derived: sum of 2 quarters · filed 2021-11-08 | -$46.39M 10-Q · filed 2021-11-08 | -$56.73M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$15.03M 10-Q · filed 2021-08-12 | -$27.91M 10-Q · filed 2021-08-12 | -$38.25M derived: sum of 3 quarters · filed 2021-08-12 | -$46.40M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$12.88M 10-Q · filed 2021-05-07 | -$23.22M derived: sum of 2 quarters · filed 2021-05-07 | -$31.37M derived: sum of 3 quarters · filed 2021-05-07 | -$38.37M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | -$10.34M 10-K · filed 2021-03-25 | -$18.49M derived: sum of 2 quarters · filed 2021-03-25 | -$25.49M derived: sum of 3 quarters · filed 2021-03-25 | -$29.33M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$8.15M 10-K · filed 2021-03-25 | -$15.15M derived: sum of 2 quarters · filed 2021-03-25 | -$18.99M 10-Q · filed 2020-11-10 | -$22.03M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | -$7.00M 10-K · filed 2021-03-25 | -$10.84M 10-Q · filed 2020-08-11 | -$13.89M derived: sum of 3 quarters · filed 2021-03-25 | -$16.23M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | -$3.84M 10-K · filed 2021-03-25 | -$6.89M derived: sum of 2 quarters · filed 2021-03-25 | -$9.23M derived: sum of 3 quarters · filed 2021-03-25 | -$11.14M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | -$3.05M 10-K · filed 2020-03-24 | -$5.38M derived: sum of 2 quarters · filed 2020-03-24 | -$7.30M derived: sum of 3 quarters · filed 2020-03-24 | -$8.90M 10-K · filed 2020-03-24 |
| 2018-09-30 | -$2.34M 10-K · filed 2020-03-24 | -$4.25M derived: sum of 2 quarters · filed 2020-03-24 | -$5.86M derived: sum of 3 quarters · filed 2020-03-24 | |
| 2018-06-30 | -$1.91M 10-K · filed 2020-03-24 | -$3.52M derived: sum of 2 quarters · filed 2020-03-24 | ||
| 2018-03-31 | -$1.60M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |